As a new investor I am at a loss to know why this little gem never goes anywhere

Is is a medical company with no debt, a profit!, minimal market capital and some interesting products.

We're in the shares4 schools contest and we'd like this babe to fly!

Yes just logged on surprising to see the number of buys after the mark down earlier today.Volume nearing 2m with a couple of nice buys thrown in,(our Friday buyer perhaps)talk of the world distribution deal also in the background nice to see a bit of interest today,practice for the real action to come.

charts are negative.this should be trading at under 1p in a few weeks

Some Director involvement this week prior to news of the worldwide sales agreement?

Todays Independent 1.11.O4
Surgical Innoations is being circled by brokers keen to snatch the company away from its current adviser,Westhouse.
A new broker it says could bring acquisition opportunities to the company, then SI shares could be worth watching.

Looks like the sun will shine now with news yesterday - deal with Rolls Royce.
Any one any comment!!! p/271

Yes it did!

Hurray!

Yes it did!

Nice one!

An interesting few days ahead of us..........Results next week should be fine and given the bumper start to the new year the share should move up. They're dancing around the year low is 50% possible in 10 days?

Fingers crossed.

Preliminary Results

Financial highlights
· Revenue of £7.64m (2011: £7.60m)
§ SI branded sales up 12.9% to £5.33m (2011: £4.73m) - representing 68% of total revenue
· Gross profit up 7.3% to £3.86m (2011: £3.60m)
· Gross margins improved to 50.5% (2011: 47.3%)
· Adjusted EBITDA (excluding exceptional items) of £2.89m (2011: £2.83m)
· Operating profit reduced to £1.32m (2011: £1.77m) - due to amortisation and exceptional costs
· Pre-tax profit reduced to £1.23m (2011: £1.71m)
· Adjusted earnings per share of 0.35p (2011: 0.44p)
· Net cash from operating activities of £612,000 (2011: £1.78m) - reflecting increase in working capital as a result of significant sales in December 2012

Operational highlights
· Strong second half sales with contracted orders in H2 of £5.62m up 85% on H1 (with c. £1m to be recognised in y/e 31 December 2013)
· US direct sales up 21.9% to £2.15m (2011: £1.76m) and are now 28.1% of total revenue (2011: 23.2%)
· 33% increase in unit sales of YelloPort+plus™ valves and swingtops
· YelloPort+plus™ cannula sales increased to 10,124 units (2011: 5,272 units) - will drive long term valve sales
· RGF grant of up to £5.05m to fund capital expansion strategy
· FDA approvals and US contracts provide a solid base for development of US strategy
· UK SI branded sales up 34.3% as more NHS hospitals convert to cost-saving Resposable® products
· New areas of MIS progressing well, particularly ultra-MIS (3mm) and hip arthroscopy

Surgical Innovations Group - Preliminary results

Audio Webcast

Senior Appointment of President of US Sales and Operations

Development agreement for Industrial application

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of creative solutions for minimally invasive surgery ('MIS'), announces that it has received funding approval with its long standing industrial partner worth over GBP210,000. The funding will be used to develop a bespoke solution for a device delivery system to be used in the on-wing inspection of jet engines.

This new funding stream follows a feasibility study carried out in 2012 and revenues relating to the project will be in addition to existing revenues from the use of SI's patented articulating segment technology in jet engine inspection and maintenance. In 2012, revenues from SI's industrial division contributed GBP101,000 (2011: GBP70,000).

SI's Endoflex(TM) Industrial product has been specially adapted to industrial applications and is based on core technology developed over the years in its surgical devices business. The product is designed to deliver tools, devices, sensors and probes precisely and repeatedly to a given target zone in a variety of industrial applications. Endoflex(TM) Industrial can provide access into inaccessible or hazardous spaces and minimises the need to disassemble complicated equipment and systems.

Graham Bowland, Chief Executive Officer for Surgical Innovations, said: "I am delighted that we continue to develop this relationship with our key industrial partner. If the development project is successful, there is a good opportunity to roll-out a number of these devices in 2014. We continue to seek opportunities where SI's intellectual property can be adapted to provide industrial solutions for major international companies."

New US dealer

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of creative solutions for minimally invasive surgery ('MIS'), announces the appointment of a US distributor, the first new US dealer since the appointment of Rick Barnett as President of US Sales and Operations.

The distributor will promote SI's Logi™ Range and YelloPort+plus™ products across Indiana, Kentucky and Ohio under the terms of a three year distribution agreement.

The established distributor is based in Indianapolis and through its dedicated sales team will cover in excess of 430 hospitals across the three designated US States.

Graham Bowland, Chief Executive Officer for Surgical Innovations, said: "This contract is evidence of SI's strategy to penetrate the US market and optimise the opportunity located there. Rick Barnett was appointed at the beginning of the month and in this short period of time has already secured this new distributor, which will help develop SI's presence in the US. Other US dealer agreements are in the pipeline and the market will be updated accordingly."


- ENDS -

Just gone back in........The interims next month should benefit from the profits too late to go into last year's finals!

Trading Update

SI has had a strong first six months of the financial year and continues to trade in line with market expectations for the full year. Revenues for the six months ended 30 June 2013 were 28% ahead of the same period last year at £3.88m (H1 2012: £3.02m) with an adjusted EBITDA for the period of £1.14m (H1 2012: £0.98m), a 16% improvement on the previous period. Profit before tax for the period of £567,000 (H1 2012: £181,000) has more than tripled.

Within the SI Brand business, the YelloPort+plus™ Port access system continued to gain UK market share as a cost effective solution for laparoscopic surgical procedures. Further to the update provided in the AGM Statement on 19 June 2013, two additional UK hospitals have converted to using our Resposable® products, one to the YelloPort+plus™ system and one to using Logi™Cut scissors. This takes the total number of hospitals converted this year to 25. The UK success of SI Branded products promotes adoption within our targeted export markets, with the US a primary focus for the Company where hospital cost reduction programmes are becoming an ever increasing phenomenon. Both orders and interest to date, ledby our newly appointed President of US Sales and Operations, are very encouraging as we expand our Brand exposure in the US.

The OEM business primarily focused on sales of instrumentation and retraction devices, driven by a demand from the existing OEM customer base. Revenues from Industrial applications will benefit from the recently announced development project with our long standing partner, due for completion at the end of 2013.

Hip Arthroscopy
SI are partnering with JRI, a leading UK Orthopaedic company to investigate how early stage osteoarthritis of the hip can be treated using minimally invasive techniques. The collaboration has recently been allocated a £390,000 grant from the TSB Biomedical Catalyst Fund to support the project, which will see SI further translate its access and articulation technologies into hip arthroscopy to enable and deliver new advanced therapeutic treatments.

Update on new facility
In January SI announced that it had formally signed the Regional Growth Fund ("RGF") Final Grant Offer Letter worth £5.05m. SI can now announce that the Board has formally approved the budget for the development of a new facility. The total cost of the building project will be funded through the RGF grant and the remainder by a commercial bank mortgage, with an estimated completion date of July 2015.

Three site locations, all situated on the Eastern side of Leeds, are being assessed for the 58,000sq ft facility which will incorporate a 10,000sq ft Clinical training centre. The Directors believe that a phased move to the new site will not have any impact on short term trading or profitability, but it is expected to bring significant operational efficiencies and the new building will be planned specifically to optimise SI's production capabilities. The Clinical training centre will act as a catalyst for innovation enabling international surgeons to develop best clinical practice in new areas of MIS, use and critique SI's latest medical device technologies and importantly enable SI to expand its development programme into new areas of MIS. The centre will combine classic training methods of laparoscopic work stations with cadaveric and dissection facilities and a simulated operating room. It is envisaged that SI will develop one of the premier facilities in the UK that will support the growing demand for clinical training both from home and abroad.

The Company will announce its interim results for the six months ended 30 June 2013 on Tuesday, 10 September 2013.

Interim Results

Financial highlights
· Revenues up 28.4% to £3.88m (H1 2012: £3.02m)
· Gross margins in core MIS business increased to 45.5% (H1 2012: 44.8%)
· EBITDA up 16.8% to £1.14m (H1 2012: £976,000*)
· Operating profit* up 18.2% to £623,000 (H1 2012: £527,000*)
· Pre-tax profit* up 19.4% to £567,000 (H1 2012: £475,000*)
· Reported pre-tax profit more than tripled to £567,000 (H1 2012: £181,000)
· Adjusted basic earnings per share of 0.12p (H1 2012: 0.09p)
· Net cash of £808,000 generated from operating activities (H1 2011: £888,000*)
*comparative adjusted to exclude H1 2012 exceptional costs of £294,000

Operational highlights
· Revenues from SI branded products up 37.7% to £2.93m (H1 2012: £2.13m)
· Revenues from OEM products down 5.2% to £0.85m (H1 2012: £0.89m)
· Strong sales of Resposable® instruments with continued disposable pull through to follow
· Revenues from SI branded disposable elements up 22.8% to £1.67m (H1 2012: £1.36m)
· Impressive 144% growth in UK SI branded product revenues to £809,000 (H1 2012: £331,000)

Post-period end highlights
· Two more distributors added to growing US distribution network
· Largest ever US order, in financial terms, for SI Branded products secured in H2

Beaufort Securities Speculative Buy 6.75 6.75 - - Initiates/Starts

This doesn't seem to be going anywhere and hasn't for a long time.?
Anyone have any ideas.

Stocking order under Surgioscopy agreement

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of creative solutions for minimally invasive surgery ('MIS'), announces it has received and dispatched an initial stocking order from Surgioscopy worth a total of £141,000.